<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04400110</url>
  </required_header>
  <id_info>
    <org_study_id>RC 10/18</org_study_id>
    <nct_id>NCT04400110</nct_id>
  </id_info>
  <brief_title>Short Therapy for Febrile UTI in Childhood</brief_title>
  <official_title>Shortened Antibiotic Therapy for Febrile Urinary Tract Infection (UTI) in Childhood: a Multicenter Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Burlo Garofolo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Burlo Garofolo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Febrile urinary tract infections (UTIs) are common in children, but there is no consensus
      concerning the duration of the antibiotic treatment. Current recommendations include the use
      of an oral antibiotic, chosen between amoxicillin and clavulanic acid or a third-generation
      cephalosporin (ceftibuten), for a minimum of seven to a maximum of 14 days. In an antibiotic
      overuse-sparing model, proper evaluation of a shorter therapy in the treatment of febrile UTI
      in childhood is lacking.

      The objective of this randomized controlled trial is to assess the non inferiority of a five
      days oral course of amoxicillin and clavulanic acid vs the standard 10-day regimen in the
      treatment of febrile UTIs in children.

      The trial results might provide evidence of the non-inferiority of a short duration of the
      antibiotic course for the treatment of febrile UTI in childhood, contributing to a reduction
      in the over-use of antibiotics and consequently limiting the emergence of antibiotic
      resistance.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of infection recurrence</measure>
    <time_frame>within 30 days after the end of the intervention</time_frame>
    <description>Infection recurrence rate is defined as the reappearance of signs and symptoms of febrile UTI by the first day after the end of antibiotic therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of complete resolution of signs and symptoms</measure>
    <time_frame>within 30 days after the end of the intervention</time_frame>
    <description>The complete resolution of the signs and symptoms (clinical assessment and urinalysis) related to the infection evaluated at the end of the treatment, without the need for additional or alternative antibiotic therapy (short term clinical efficacy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of antibiotic-resistant or of opportunistic strains in relapses</measure>
    <time_frame>within 30 days after the end of the intervention</time_frame>
    <description>Antibiotic resistance is defined as the presence of positive urinalysis and positive urine culture for a single type of bacterium resistant to amoxicillin and clavulanic acid, after treatment in case of relapse. The bacterial growth will be considered significant if &gt;105 colony-forming unit/ml (CFU/ml) (&gt;104 CFU/ml for urine samples collected by bladder catheterization). Urine cultures containing more than one bacterial species will be considered contaminated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">520</enrollment>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Short treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amoxicillin and clavulanic acid 50 mg/kg three times daily administered orally for 5 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>amoxicillin and clavulanic acid 50 mg/kg three times daily administered orally for 10 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin and Clavulanic Acid in Oral Dose Form</intervention_name>
    <description>50 mg/kg three times daily administered orally</description>
    <arm_group_label>Short treatment group</arm_group_label>
    <arm_group_label>Standard treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age from 3 months to 5 years;

          2. Clinical diagnosis of febrile UTI, defined by fever ≥38°C and positive result of
             urinalysis (nitrite and/or leukocyte esterase positivity) in two consecutive urine
             samples collected by bladder catheterization or clean catch (19). The diagnosis of UTI
             will be then confirmed by positive urine culture for a single type of bacterium with a
             charge&gt; 105 CFU /ml as per the Recommendations of the Italian Society of Pediatric
             Nephrology (SINePe) (19).

        Exclusion Criteria:

          1. &quot;Complicated&quot; febrile UTI (septic appearance, repeated vomiting impeding oral
             administration of the antibiotic, severe-moderate dehydration with the need for
             intravenous antibiotic therapy)

          2. Presence of an inserted urinary catheter

          3. Immunodeficiency

          4. Hypersensitivity to the active substance or other beta-lactam antibiotics

          5. Any antibiotic treatment received in the previous 15 days.

          6. Presence of another poorly controlled chronic medical condition (diabetes,
             inflammatory bowel disease, etc.)

          7. Presence of neurological bladder

          8. Presence of phenylketonuria or glucose-galactose malabsorption

          9. Intestinal malabsorption

         10. Poor compliance

         11. History of jaundice or liver failure positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Egidio Barbi, MD Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Institute for maternal and child health Burlo Garofolo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco Pennesi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for maternal and child health Burlo Garofolo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marco Pennesi, MD</last_name>
    <phone>040-3785263</phone>
    <email>marco.pennesi@burlo.trieste.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefano Amoroso, MD</last_name>
    <phone>+393294470215</phone>
    <email>stefanoamoroso1234@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Policlinico S.Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <state>Emilia Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudio La Scola, MD</last_name>
      <phone>0512144617</phone>
      <email>claudio.lascola@aosp.bo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santa Maria delle Croci Hospital</name>
      <address>
        <city>Ravenna</city>
        <state>Emilia Romagna</state>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Federico Marchetti, MD</last_name>
      <phone>0544-285518</phone>
      <email>federico.marchetti@auslromagna.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Polo</name>
      <address>
        <city>Monfalcone</city>
        <state>Friuli Venezia Giulia</state>
        <zip>34074</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cristina Milocco, MD</last_name>
      <phone>0481-487233</phone>
      <email>cristina.milocco@aas2.sanita.fvg.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pediatric Department, Santa Maria degli Angeli Hospital</name>
      <address>
        <city>Pordenone</city>
        <state>Friuli Venezia Giulia</state>
        <zip>33170</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laura Cesca, MD</last_name>
      <phone>0434 399421</phone>
      <email>laura.cesca@aas5.sanita.fvg.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute for Maternal and Child Health IRCCS Burlo Garofolo</name>
      <address>
        <city>Trieste</city>
        <state>Friuli Venezia Giulia</state>
        <zip>34137</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Pennesi, MD</last_name>
      <phone>040-3785263</phone>
      <email>marco.pennesi@burlo.trieste.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASUIUD Azienda sanitaria universitaria integrata di Udine</name>
      <address>
        <city>Udine</city>
        <state>Friuli Venezia Giulia</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michela Vergine, MD</last_name>
      <phone>0432-559880</phone>
      <email>michela.vergine@asuiud.sanita.fvg.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Agostino Gemelli - IRCCS City Rome</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Gatto, MD</last_name>
      <phone>0630154290</phone>
      <email>antonio.gatto@policlinicogemelli.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCSS Ca Granda, Policlinico di Milano</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Montini, MD</last_name>
      <phone>02.55032336</phone>
      <email>giovanni.montini@unimi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti di Ancona - Ospedale Salesi</name>
      <address>
        <city>Ancona</city>
        <state>Marche</state>
        <zip>60123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabrizio Pugliese, MD</last_name>
      <phone>071-5962016</phone>
      <email>fabrizio.pugliese@yahoo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U.G. Martino</name>
      <address>
        <city>Messina</city>
        <state>Sicilia</state>
        <zip>98124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto Chimenz</last_name>
      <phone>090/2212119</phone>
      <email>roberto.chimenz@polime.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Martino Hospital</name>
      <address>
        <city>Belluno</city>
        <state>Veneto</state>
        <zip>32100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giangiacomo Nicolini, MD</last_name>
      <phone>0437-516231</phone>
      <email>gnicolini@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Woman and Child Health, University of Padua City</name>
      <address>
        <city>Padua</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liviana Da Dalt, MD Prof</last_name>
      <phone>049 8211403</phone>
      <email>liviana.dadalt@unipd.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UOC Pediatria Ospedale Ca' Foncello</name>
      <address>
        <city>Treviso</city>
        <state>Veneto</state>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Floriana Scozzola, MD</last_name>
      <phone>0422 322297</phone>
      <email>floriana.scozzola@aulss2.veneto.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 19, 2020</study_first_submitted>
  <study_first_submitted_qc>May 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2020</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>short antibiotic therapy</keyword>
  <keyword>urinary tract infection</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

